Axonics Modulation Technologies

Founded in 2013 by co-founders Guangqiang Jiang and Raymond W. Cohen and based in California, US, Axonics Modulation Technologies, Inc. develops a rechargeable neuromodulation platform for the treatment of urinary and fecal dysfunction. In January 2024, Boston Scientific Corporation agreed to acquire Axonics Modulation Technologies, Inc. for USD 71 per share. The acquisition valued Axonics Modulation Technologies, Inc.7 billion post-money. The transaction was completed in November 2024. Axonics' core offering is the Axonics Therapy system, a minimally invasive treatment that leverages sacral neuromodulation (SNM) technology. SNM therapy involves implanting a medical device that delivers mild electrical pulses to the sacral nerves, which helps in regulating bladder and bowel function. This approach improves symptoms for patients struggling with conditions like overactive bladder, fecal incontinence, and non-obstructive urinary retention. The Axonics implant is MRI-safe, allowing patients to undergo magnetic resonance imaging scans without complications.

1. Series C

   Jul 6, 2017

   Amount

   $21M

   Investors

   Locked

2. Series C

   May 2, 2017

   Amount

   $15M

   Investors

   Locked

3. Series B

   Dec 21, 2015

   Amount

   $39M

   Investors

   Locked

4. Series A

   Mar 14, 2014

   Amount

   $14M

   Investors

   Locked